• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌患者的静脉血栓栓塞:循环组织因子的影响

Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor.

作者信息

Delluc Aurélien, Rousseau Aurélie, Delluc Céline, Le Moigne Emmanuelle, Le Gal Grégoire, Mottier Dominique, Van Dreden Patrick, Lacut Karine

机构信息

Département de Médecine Interne et Pneumologie, Faculté de Médecine et des Sciences de la Santé, Université de Brest, CHU de Brest, Brest, France.

出版信息

Blood Coagul Fibrinolysis. 2011 Jun;22(4):295-300. doi: 10.1097/MBC.0b013e32834512f4.

DOI:10.1097/MBC.0b013e32834512f4
PMID:21372691
Abstract

Among cancers, pancreatic cancer is known to be associated with a higher incidence of venous thromboembolism (VTE). The aim of the study was to determine the implication of circulating tissue factor (TF) in VTE related to active pancreatic cancer. One hundred and sixty-four consecutive patients who participated to the Etude des Determinants et Interactions de la Thrombose veineuse (EDITH) study between January 2005 and August 2007 for symptomatic VTE related to active pancreatic cancer (n = 8), active cancer of other location (n = 42) or classified as unprovoked (n = 114) were included. TF activity (TFa) was measured in a one-stage kinetic chromogenic method. There were no differences of median TFa levels between patients with VTE related to cancer of other type than pancreas [2.01 pmol/l range (0.05-43.92)] and patients with unprovoked VTE [1.78 pmol/l (range 0.05-63.72), P = 0.21]. Median TFa levels were higher in patients with VTE related to pancreatic cancer [12.67 pmol/l (range 0.05-112.04)] than in patients with VTE related to cancer of other type [2.01 pmol/l (range 0.05-43.92), P = 0.02]. Higher levels of circulating TFa during the course of pancreatic cancer may explain the higher incidence of VTE associated with this type of cancer.

摘要

在各类癌症中,胰腺癌与静脉血栓栓塞(VTE)的较高发病率相关。本研究的目的是确定循环组织因子(TF)在与活动性胰腺癌相关的VTE中的作用。纳入了2005年1月至2007年8月期间连续参加静脉血栓形成的决定因素和相互作用研究(EDITH)的164例患者,这些患者因与活动性胰腺癌相关的有症状VTE(n = 8)、其他部位的活动性癌症(n = 42)或归类为不明原因(n = 114)而参与研究。采用一步动力学显色法测量TF活性(TFa)。与其他类型癌症相关的VTE患者[2.01 pmol/l范围(0.05 - 43.92)]和不明原因VTE患者[1.78 pmol/l(范围0.05 - 63.72),P = 0.21]的TFa水平中位数无差异。与胰腺癌相关的VTE患者的TFa水平中位数[12.67 pmol/l(范围0.05 - 112.04)]高于与其他类型癌症相关的VTE患者[2.01 pmol/l(范围0.05 - 43.92),P = 0.02]。胰腺癌病程中循环TFa水平较高可能解释了与这种类型癌症相关的VTE发病率较高的原因。

相似文献

1
Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor.胰腺癌患者的静脉血栓栓塞:循环组织因子的影响
Blood Coagul Fibrinolysis. 2011 Jun;22(4):295-300. doi: 10.1097/MBC.0b013e32834512f4.
2
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.伴有和不伴有静脉血栓栓塞症的癌症患者中的内皮细胞、血小板和组织因子载带的微粒。
Thromb Res. 2011 May;127(5):473-7. doi: 10.1016/j.thromres.2011.01.002. Epub 2011 Jan 22.
3
Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).特发性与风险相关静脉血栓栓塞的心血管危险因素比较:关注纤维蛋白原、因子 VIII 和高敏 C 反应蛋白 (hs-CRP)。
Thromb Haemost. 2009 Oct;102(4):668-75. doi: 10.1160/TH-09-02-0104.
4
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.D-二聚体和凝血酶原片段1+2可预测癌症患者发生静脉血栓栓塞:来自维也纳癌症与血栓形成研究的结果。
J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27.
5
Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.I期临床中晚期难治性癌症患者静脉血栓栓塞并发症的临床结局及预测其发生的因素:MD安德森癌症中心的经验
Am J Hematol. 2009 Jul;84(7):408-13. doi: 10.1002/ajh.21423.
6
Postoperative venous thromboembolism predicts survival in cancer patients.术后静脉血栓栓塞预测癌症患者的生存。
Ann Surg. 2012 May;255(5):963-70. doi: 10.1097/SLA.0b013e31824daccb.
7
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients.评估胰腺癌患者静脉血栓栓塞的风险和死亡率。
Anticancer Res. 2010 Oct;30(10):4261-4.
8
Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.528,693名成年人在癌症诊断前一年的静脉血栓栓塞发病率。
Arch Intern Med. 2005;165(15):1782-7. doi: 10.1001/archinte.165.15.1782.
9
Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.体重调整剂量的达肝素用于预防晚期胰腺癌患者血管血栓栓塞可降低血清组织因子及血清介导的癌细胞侵袭诱导作用。
Blood Coagul Fibrinolysis. 2010 Jul;21(5):452-8. doi: 10.1097/MBC.0b013e328338dc49.
10
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.晚期结直肠癌患者静脉血栓栓塞的发生率及临床意义:“GISCAD交替方案”研究结果
Eur J Cancer. 2009 Jan;45(1):65-73. doi: 10.1016/j.ejca.2008.09.005. Epub 2008 Dec 8.

引用本文的文献

1
A new era: tumor microenvironment in chemoresistance of pancreatic cancer.新时代:胰腺癌化疗耐药中的肿瘤微环境
J Cancer Sci Clin Ther. 2022;6(1):61-86. doi: 10.26502/jcsct.5079146. Epub 2022 Feb 15.
2
Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer.嘌呤能信号在胰腺中的作用——从生理学角度到胰腺癌的治疗策略。
Int J Mol Sci. 2020 Nov 20;21(22):8781. doi: 10.3390/ijms21228781.
3
Hypercoagulability After Resection of Thoracic Malignancy: A Prospective Evaluation.胸部恶性肿瘤切除术后的高凝状态:前瞻性评估。
World J Surg. 2019 Dec;43(12):3232-3238. doi: 10.1007/s00268-019-05123-7.
4
The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance.血小板衍生的ADP和ATP在促进胰腺癌细胞存活及吉西他滨耐药中的作用
Cancers (Basel). 2017 Oct 24;9(10):142. doi: 10.3390/cancers9100142.
5
Targeting Platelets for the Treatment of Cancer.靶向血小板用于癌症治疗
Cancers (Basel). 2017 Jul 22;9(7):94. doi: 10.3390/cancers9070094.
6
Pancreatic Cancer-Induced Neutrophil Extracellular Traps: A Potential Contributor to Cancer-Associated Thrombosis.胰腺癌诱导的中性粒细胞胞外陷阱:癌症相关血栓形成的潜在促成因素。
Int J Mol Sci. 2017 Feb 24;18(3):487. doi: 10.3390/ijms18030487.
7
Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes.远不止于特鲁索综合征。胰腺副肿瘤综合征的广泛谱系。
Pathol Oncol Res. 2018 Jan;24(1):1-10. doi: 10.1007/s12253-017-0206-6. Epub 2017 Feb 3.
8
Tumor-Derived Tissue Factor Aberrantly Activates Complement and Facilitates Lung Tumor Progression via Recruitment of Myeloid-Derived Suppressor Cells.肿瘤衍生的组织因子通过募集髓源性抑制细胞异常激活补体并促进肺肿瘤进展。
Int J Mol Sci. 2017 Jan 19;18(1):22. doi: 10.3390/ijms18010022.
9
Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression.癌细胞系释放含组织因子微囊泡的潜力分析:与组织因子及PAR2表达的相关性
Thromb J. 2016 Jan 19;14:2. doi: 10.1186/s12959-016-0075-3. eCollection 2016.
10
Simulated Thrombin Generation in the Presence of Surface-Bound Heparin and Circulating Tissue Factor.表面结合肝素和循环组织因子存在下的模拟凝血酶生成
Ann Biomed Eng. 2016 Apr;44(4):1072-84. doi: 10.1007/s10439-015-1377-5. Epub 2015 Jul 14.